CD40LG and relapsing-remitting multiple sclerosis: Our research group has found that patients with RRMS with IgG and IgM antibodies (IgG+/IgM+) have less energy to repair axonal lesions, due to repression of genes related to ATP production, so they have more aggressive clinical symptoms and greater inflammation compared to IgG+/IgM− patients [145].